CELU
Celularity Inc
1.20$
-2.5%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -36.2% | +0.0% | -8.5% | +0.1% | -10.5% | +3.0% | +0.0% | -9.3% | -5.0% | -6.0% | +0.0% | |
| – | -8.5% | +0.0% | +38.5% | -13.4% | -26.7% | +41.8% | +0.0% | -16.0% | -38.6% | +16.3% | +0.0% | |
| – | -91.1% | +0.0% | +596.7% | -88.1% | -41.4% | +454.9% | +0.0% | +16.9% | -86.1% | +5,045.8% | +0.0% | |
| – | – | – | – | – | -41.4% | – | – | +16.9% | -86.1% | – | – | |
| – | -15.8% | +50.4% | +122.6% | -12.0% | -27.6% | +54.6% | +0.0% | -17.7% | -39.9% | -30.6% | +0.0% | |
| – | -14.0% | +0.0% | -25.0% | +55.4% | -31.1% | +36.5% | +0.0% | -18.5% | -41.9% | -77.7% | +0.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -91.8% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -4.6% | +0.0% | -9.5% | +5.2% | -12.5% | -3.9% | +0.0% | -8.0% | -4.4% | -4.6% | +0.0% | |
| – | -0.8% | +0.0% | -11.3% | -8.6% | +8.4% | +11.0% | +0.0% | +17.7% | -7.9% | +8.2% | +0.0% | |
| – | +30.3% | +0.0% | -22.0% | +1.9% | +13.2% | -29.5% | +0.0% | +29.0% | -5.7% | +23.6% | +0.0% | |
| – | – | – | – | – | +8.6% | – | – | +9.2% | -17.6% | – | – | |
| – | +3.9% | +0.0% | +0.4% | +8.9% | +8.9% | +51.3% | +0.0% | +4.7% | +0.8% | +7.5% | +0.0% | |
| – | – | – | – | – | – | – | +1.6% | +0.0% | – | – | – | |
| – | -74.5% | +0.0% | +3.3% | +31.1% | -57.8% | -48.9% | +0.0% | -388.5% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +9.7% | -2.8% | +15.8% | -11.1% | +13.4% | +2.6% | -0.9% | +7.5% | +9.7% | +9.5% | -11.2% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.